The future of therapeutic MAbs lies in the development of economically feasible downstream processes.
Suzanne S. Farid, PhD
Advertisement
Senior Lecturer (Associate Professor) at the Advanced Centre for Biochemical Engineering, Department of Biochemical Engineering, University College London
Articles by Suzanne S. Farid, PhD
The future of therapeutic MAbs lies in the development of economically feasible downstream processes.
Advertisement
Latest Updated Articles
Economic Drivers and Trade-Offs in Antibody Purification ProcessesPublished: March 2nd 2009 | Updated:
Economic Drivers and Trade-Offs in Antibody Purification ProcessesPublished: March 2nd 2008 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
Industry Leaders Detail Transformational Strategies to Mainstream CAR-T Care
2
Why Flexibility and Commercial Viability Must Be Built-in Early for Scaling CGTs
3
How Rentschler Biopharma’s New Platforms Aim to Accelerate Biologics Development in Asia
4
Analyzing the Safety and Scope of Next-Generation Gene Editing Platforms
5
